It is made available under a CC-BY 4.0 International license .

Prevalence of and risk factors for high-risk HPV and cervical cytological abnormalities in women living with HIV in Bali, Indonesia

3

I Ketut Agus Somia¹, Made Lady Adelaida Purwanta², Ni Wayan Winarti³, Ida Bagus Nyoman 4 Putra Dwija⁴, Desak Made Putri Pidari⁵, A.A.S. Sawitri⁶, Anak Agung Ayu Yuli Gavatri⁷, I 5 Nyoman Gede Budiana⁸, Komang Januartha Putra Pinatih⁹, Ketut Tuti Parwati Merati¹⁰ 6 ^{1,3,7,8} Prof dr IGNG Ngoerah Hospital – Faculty of Medicine, Udayana University Denpasar Bali 7 ^{2,,4,6,9,10}Faculty of Medicine, Udayana University Denpasar Bali 8 ⁵Kerti Praja HIV Foundation Clinic Denpasar Bali 9 *Corresponding author: I Ketut Agus Somia; Department of Internal Medicine, Tropical and 10 Infectious Disease Division, Udayana University/Prof. dr. I.G.N.G Ngoerah General Hospital, 11 12 Denpasar, Bali, Indonesia; email: agus somia@yahoo.co.id 13 Abstract 14 Background: Women living with HIV face a higher risk of developing cervical cancer compared to those without HIV. However, comprehensive cervical cancer screening programs for this 15 population are still lacking in Indonesia. This has resulted in many cases of late-stage cervical 16 cancer being diagnosed, especially in Bali, which has experienced an increase in cases of HIV and 17 cervical cancer. This study aimed to determine the prevalence of and risk factors for cervical 18 cytological abnormalities in women living with HIV in Bali and to explore their relationship with 19 high-risk HPV (HR-HPV) types. 20 Methods: This is a cross-sectional study with eligible participants recruited from outpatient HIV 21

clinics in Bali. Between July to December 2023, participants were interviewed to collect
demographic and historical medical information, followed by physical examination including
collection of cervical swabs and blood samples. Pap smear sampling and swab collection using
ThinPrep for cytology. HPV DNA was then identified by PCR and genotyped for HR-HPV

16,18,31,33,35,39,45,51,52,56,58,59,66,68. Blood samples were analyzed for CD4 and CD8 cell
counts.

Results: A total of 245 women with HIV at median age of 38 years old (24-50 years) and with 28 29 median time of ARV therapy of 7 years (0-18 years) were enrolled. Only 239 participants were 30 included in the analysis for their valid initial results. Overall, 26 (10.87%) of samples showed 31 abnormal cytology including 6 (2.5%) ASC-H, 9 (3.8%) ASC-US, 4 (1.7%) H-SIL and 7 (2.9%) 32 L-SIL. Of the 58 (24%) that tested positive for HPV DNA, 18 (31%) samples had abnormal cytology. HPV 18 was the most common genotype detected (n=16 or 28%). Bivariate analysis 33 revealed a significant association between positive HPV DNA and abnormal cytology, with those 34 35 testing HPV-positive having seven times higher risk of ASC-US or greater

36 (PR=7.022;95%CI=3.223-15.295). Multivariate regression identified having HPV 18 infection as

It is made available under a CC-BY 4.0 International license .

- an independent risk factor for abnormal cytology (ExpB=9.029;p=0.007), and a history of Pap smear screening associated with reduced risk of HR-HPV infection (ExpB=0.358;p=0.013).
- **Conclusion:** In our study, 10.87% of women living with HIV had abnormal cytology and 24%
- 40 had positive HPV DNA tests. HPV 18 was associated with a greater risk of abnormal cytology
- 41 compared to other high-risk HPV strains, but our sample size was small. History of pap smear was
- 42 also shown to decrease the risk of HR-HPV infection. The results underscore the need for increased
- 43 vaccination of younger women and screening of all women living with HIV in Indonesia in order
- 44 to improve their cervical health outcomes.
- 45

Keywords: High-risk HPV, cervical abnormalities, cervical cytological abnormalities, HIV, risk
factors

48

49 Introduction

Cervical cancer is one of the most frequently detected cancers in women living with HIV 50 and is classified as an AIDS-defining illness. From the meta-analysis of 24 studies shows that 51 women living with HIV have six times higher risk of developing cervical cancer compared to those 52 without HIV.(1) Globally, an estimated 6% of new cervical cancer cases in 2018 were diagnosed 53 among women living with HIV and 5% of all cases were attributable to HIV infection.¹ IARC 54 2021 data shows that in Indonesia, 0.3% of cervical cancer cases were caused by co-infection with 55 56 HIV. Due to being immunocompromised, women living with HIV are more prone to high-risk HPV strains that often cause cervical cancer, this could even result in the persistence of the HPV 57 infection.(2,3) This leads to the urgency in early detection and management of cervical cancer in 58 the population of women living with HIV. 59

60 Cervical cancer screening in HIV population is crucial to avoid further complication and mortality. Screening is the main strategy to reduce cervical cancer incidence, by detecting pre-61 cancerous lesions that can be treated before evolving to cancer. This, which is followed by 62 adequate management is one of two prevention tools recommended by WHO that are highly 63 effective. Based on CDC guidelines, for woman with newly diagnosed HIV-infection, the first 64 65 cervical cancer screening is recommended by the time of HIV diagnosis and repeated on 6 or 12 months after diagnosis.(4) Effectiveness of the disease's management is influenced by not only 66 the accuracy of the screening method but also by the coverage of the cervical cancer treatment. 67 However, in reality many countries have yet conducted established screening program for cervical 68 cancer in this specific population, especially those of developing countries. 69

Indonesia was still considered at a low rate of cervical cancer screening (12%) per 2020, resulting in an emergency situation for cervical cancer until recently.(5) Many patients came to the hospital with their end-stage cancer due to the late diagnosis. On the other hand, there has also been increasing number of HIV cases. Based on the recapitulation data of the early detection of cervical cancer in Indonesia 2016, the number of suspected cervical cancer in several provinces such as Jakarta were 269 cases, Bali with 254 cases and Bangka Belitung with 227 cases. The data showed that Bali was one of the areas with high cervical cancer rates in 2016. Furthermore,

It is made available under a CC-BY 4.0 International license .

this number increased in 2019 for Bali with the incidence of cervical cancer of 437 cases. On the

other hand, Bali was on the sixth position for the highest HIV cases in Indonesia with 28,376 cases

until June 2022 as stated by the Indonesian Ministry of Health June 2022.(6)However, there has

80 yet been any data on the number of cervical cancer in this HIV population.

81 A number of risk factors could also influence the risk of cervical cytological abnormalities and cervical cancer in women living with HIV. Besides late screening, it was thought that late 82 ART initiation or at lower CD4 cell counts could increase the risk of developing cervical cancer. 83 ART are expected to decrease viral load and help improve CD4 cell counts, thus enhancing 84 clearance of HPV and reducing the incidence of cervical cytological abnormalities.(2) Therefore, 85 inequities in access to effective cervical cancer screening and treatment of precancerous cervical 86 lesions are likely to be the main driver of high invasive cervical cancer rates in women living with 87 HIV. 88

Due to the reasoning above, we would like to determine the prevalence and risk factors of cervical cytological abnormalities in women living with HIV in Bali, Indonesia, as well as to find its association with the high-risk HPV possible of cervical cancer. This study will provide not only the actual data of the local population to define future action in eradicating cervical cancer, but also directly provide benefit in the form of early detection for women living with HIV in Bali.

94 Methods

95 *Study design and setting*

This research was an observational study with cross-sectional design carried out at Yayasan
Kerti Praja HIV foundation Denpasar Bali clinic 26th of July 2023 – 11th of December 2023. The
respondents were women living with HIV who had regular appointments at the HIV clinics in Bali.
All participants gave their consent by signing on a written informed consent. This study has been
granted an ethical statement from the Ethic Committee of Faculty of Medicine, Udayana
University with the number: 1661/UN14.2.2.VII.14/LT/2023.

102

103 Patient selection and sampling

We included all women living with HIV of age 18-50 years old that attended the clinics. The inclusion criteria: 1) women living with HIV of age 18-50 years old; 2) Indonesian nationality; 3) has had sexual intercourse and willing to give their informed consent and exclusion criteria: 1) mentally unstable; 2) cervical cancer patients; 3) on menstruation during data collection; 4) pregnant women; 5) history of previous pap smear and/or HPV testing in the last 6 months; 6) on treatment of all types of pre-malignancy or malignancy and/or had hysterectomy.

Number of samples were calculated based on the sample size formula for cross-sectional design of proportional outcome. With the level of acceptable error of 5% and the expected proportion in population of 19.05%,(7) and at the 5% types I error rate, the minimum number of samples required was 237. Potential candidates were approached with consecutive sampling.

We screened 300 eligible candidates of women living with HIV, where these women had no certain symptoms, but rather concern regarding their predisposition to the disease. The screening procedure was done in a similar way to one of the algorithms (Algorithm 3) in the WHO Guidelines

- of Cervical Cancer Screening.(8) For research purpose, all participants in the study went through
- 118 cytology screening with ThinPrep pap smear and HPV DNA testing simultaneously. This was
- done altogether to give a complete picture of all participants involved in this study as part of the
- 120 Indonesian ethnicity.
- 121

122 Study procedures

- 123 Blood samples were analyzed for CD4 and CD8 cell counts using the flow cytometry method using
- 124 FACSVia (R656874100022) / FASClyric tool (R659180000700)

125 Cytology identification

- 126 Cytological tests were performed by liquid based preparation technique (ThinPrep, Hologic, Inc.,
- 127 USA). All specimens were taken using ThinPrep swab kit, processed with a ThinPrep machine,
- stained with Papaniculaou stain, and assessed microscopically by a pathologist based on The
- 129 Bethesda System criteria.

130 PCR for HPV DNA and genotyping

Vaginal swab samples were collected and inserted into ThinPrep cytology media (ThinPrep 131 PreservCyt Solution1 REF 70097-005-Hologic, Inc. Marlborough, MA, USA). Subsequently, 132 the fluid in the cytology tube was vortexed, and 1 ml of ThinPrep fluid was transferred to a 133 microcentrifuge tube. Centrifugation was performed at 12,000 RPM for 1 minute, and the pellet 134 was washed with distilled water. DNA extraction was carried out using the Zymo Quick-DNATM 135 Miniprep Plus Kit according to the manufacturer's instructions. The extracted DNA was then 136 stored at -20°C until use. Next, PCR was performed with a total volume of 10 µl, consisting of 10 137 nM forward and reverse primers, PCR mix, and distilled water. PCR was conducted in two stages; 138 the first stage used the MY09/11 universal primers, and positive samples were followed by type-139 specific PCR using specific primers for HPV 16,18,31,33,35,39,45,51,52,58,59,66,68, and 69. 140 PCR was carried out on a VeritiTM machine (AB Biosystem) with a denaturation PCR program 141 of 95°C for 5 minutes, followed by 35 cycles of 95°C for 1 minute, 95°C for 20 seconds, 55°C for 142 45 seconds, 72°C for 60 seconds, and a final extension at 72°C for 7 minutes. PCR results were 143 visualized using 1.5% agarose gel with GelRed staining under UV light 144

145

146 Statistics

147 Initially, descriptive statistics were used to summarize the demographic and clinical characteristics of the study population. The prevalence of cervical abnormalities and HPV 148 infection rates were calculated. Bivariate analysis was conducted to explore the association 149 between HPV DNA positivity and abnormal cytology results. The strength of this association was 150 quantified using odd ratio (ORs) with corresponding 95% confidence intervals (CIs). Multivariate 151 logistic regression analysis was then performed to identify independent risk factors for cervical 152 abnormalities, adjusting for potential confounders that had association in bivariate analysis of less 153 than 0.25. The significance of multivariate analysis was determined with a threshold of p-value 154 less than 0.05. We used SPSS version 29 to conduct the analysis. 155

156

It is made available under a CC-BY 4.0 International license .

157 **Results**

From the targeted population, we received a list of 300 potential candidates for screening. 158 After referred to the inclusion and exclusion criteria, we recruited 245 eligible participants, from 159 which 239 samples (97.6%) were successfully analyzed. We had to repeat sampling 10 cases due 160 161 to initial sampling inadequacy, attributed to challenging conditions such as difficult portio access or the presence of inflammatory cells. The research team gave significant efforts to communicate 162 with participants requiring re-sampling, providing detailed explanations about the importance of 163 the repeat pap smear procedure and the potential health benefits. Out of these ten needed to repeat, 164 there were six samples excluded from the final analysis, two of these were due to suspected 165 cervical cancer, and the other four were due to logistical issues (two participants relocated and 166 could not return, and two declined to participate further despite multiple contact attempts, resulting 167 in lost to follow up). The team still provided results from the initial tests along with health education 168 and preventive advice concerning cervical cancer (see Figure 1). 169

170



171 172

Figure 1. Recruitment process during the study

173

174 Baseline characteristics of study participants

Based on Table 1, the characteristics of study participants were grouped based on the 175 presence or absence of cervical cytological abnormalities, categorized across various demographic 176 and behavioral factors. The findings indicated that divorced individuals represented 8.8% of those 177 178 with cytological abnormalities, while 91.3% did not have these conditions. Education levels 179 revealed a slightly higher incidence cytological abnormalities among those with higher education, with those having completed high school or more showing a greater percentage compared to those 180 with less education. Employment status correlated with cytological abnormalities prevalence, 181 182 where 15.5% of unemployed participants had cytological abnormalities compared to 8.9% of employed participants. The analysis also considered lifestyle factors such as alcohol consumption 183

It is made available under a CC-BY 4.0 International license .

and contraception use, noting that none of the alcohol consumers in the study had cytological abnormalities, and those using contraception exhibited a higher percentage of cytological abnormalities than those who did not. Sexual behavior was also a factor, with participants who had more sexual partners or an earlier sexual debut showing slightly higher percentages of cytological abnormalities. Additional factors like gravidity, hormonal medication use, and history of abortion were examined, each contributing to the understanding of how these characteristics were associated with the presence of ASC or cervical cytological abnormalities among the participants.

Table 1. Characteristics of samples based on with and without cervical cytological abnormalities(categorical variables)

	With cytological	tological Without cytological		Odd matia
Variables	abnormalities	abnormalities	p-value	
	(n, %)	(n, %)		(93%(1)
Marital Status (n=	239)			
Divorced	7 (8.8%)	73 (91.3%)		-
Married	18 (12.8%)	123 (87.2%)	0.492	
Single	1 (5.6%)	17 (94.4%)		
Education (n=239)				
<high school<="" td=""><td>8 (9.1%)</td><td>80 (90.9%)</td><td>0.4002</td><td>-</td></high>	8 (9.1%)	80 (90.9%)	0.4002	-
≥High School	18 (11.9%)	133 (88.1%)	0.498"	
Occupation				
Unemployed	11 (15.5%)	60 (84.5%)	0.12(2	0.535 (0.232-
Employed	15 (8.9%)	153 (91.1%)	0.130^{a}	1.230)
Alcohol (n=239)				
Yes	0 (0%)	1 (100.0%)	1 000h	-
No	26 (10.9%)	212 (89.1%)	1.000°	
Contraception (n=	239)			
Yes	17 (14.5%)	100 (85.5%)	0.07(2	2.134 (0.911-
No	9 (7.4%)	113 (92.6%)	0.070^{a}	5.002)
Number of Sexual	Partner (n=239)			
≥5	6 (8.5%)	65 (91.5%)	0 4228	-
<5	20 (11.9%)	148 (88.1%)	0.435 ^a	
Sexual debut year	(n=239)			
<21	17 (10.7%)	142 (89.3%)	0.00(3	-
≥21	9 (11.3%)	71 (88.8%)	0.896ª	
Viral load (n=182))			
Detected	5 (16.1%)	26 (83.9%)	0.2203	-
Not detected	14 (9.3%)	137 (90.7%)	0.329^{a}	
HIV Duration (yea	urs) (n=239)			

It is made available under a CC-BY 4.0 International license .

≥5	15 (9.4%)	145 (90.6%)	0.288 ^a	-
<5	11 (13.9%)	68 (86.1%)		
ARV Treatment Dur	tation (Years) (n=23	9)		
≤1	6 (15.0%)	34 (85.0%)	<u>0.242</u>	-
2-4	7 (15.9%)	37 (84.1%)		
≥5	13 (8.4%)	142 (91.6%)		
Smoking status (n=2	239)			
Yes	3 (9.7%)	28 (90.3%)	1 000b	-
No	23 (11.1%)	185 (88.9%)	1.000°	
HPV infection histor	ry (n=239)			
Yes	4 (18.2%)	18 (81.8%)	0 274b	-
No	22 (10.1%)	195 (89.9%)	0.274*	
Pap smear history (n	n=239)			
Yes	7 (5.6%)	119 (94.4%)	0 005**a	0.291 (0.117-
No	19 (19.8%)	94 (83.2%)	0.005	0.721)
HPV Vaccine Status	s (n=239)			
No	26 (11.1%)	208 (88.9%)	1 000 ^b	_
Yes	0 (0%)	5 (100%)	1.000	
Gravidity (n=239)				
No gravidity	2 (7.7%)	24 (92.3%)		
≤2	12 (9.2%)	118 (90.8%)	0.420	-
>2	12 (14.5%)	71 (85.5%)		
Hormonal medication	on (n=239)			
Yes	1 (25%)	3 (75%)	0 371 ^b	_
No	25 (10.6)	210 (89.4%)	0.571	
Abortion (n=239)				
Yes	7 (8%)	81 (92%)	0 268ª	-
No	19 (12.6%)	132 (87.4%)	0.200	
History of STDs (n=	239)			
Yes	4 (19%)	17 (81%)	0 260 ^b	-
No	22 (10.1%)	196 (89.9%)	0.200	
Menopause (n=239)				
Yes	1 (4%)	24 (96%)	0.328 ^b	-
No	25 (11.7%)	189 (88.3%)		
Universal HPV DNA	A results (n=239)			
HPV (+)	18 (31.0%)	40 (69.0%)	0.000 ^a **	9.731 (3.952-
HPV (-)	8 (4.4%)	173 (95.6%)		23.959)

193 ^aanalysed by chi-square test

^banalysed by fisher's exact test

It is made available under a CC-BY 4.0 International license .

195

Based on Table 2, it was found that the average age of participants with cytological 196 197 abnormalities was slightly younger at 35.5 years compared to 38 years for those without these conditions, although this difference was not statistically significant. Notably, the CD4 cell count 198 showed a significant difference, with a median count of 415 cells/uL in those with Cytological 199 abnormalities versus 556 cells/uL in those without, suggesting a lower immune status in the 200 201 affected group. Similarly, the percentage of CD4 cells was significantly lower in participants with Cytological abnormalities, averaging 21.34%, compared to 26.62% in those without, further 202 indicating compromised immune function in the former group. The CD8 cell count and percentage 203 did not show significant differences. However, the CD4/CD8 ratio was significantly lower in 204 participants with Cytological abnormalities, with a median of 0.43 compared to 0.63 in those 205 without, underscoring a more pronounced immune system imbalance in those with cervical 206 abnormalities. 207

Variables	With cytological abnormalities (mean <u>+</u> SD or median (min-max)	Without cytological abnormalities (mean <u>+</u> SD or median (min-max)	p-value (CI95%)
Age (years)	35.5 (27-47)	38 (24-50)	0.330 ^c
CD4# (sel/uL)	415 (65-1132)	556 (103-1680)	0.011*c
CD8# (sel/uL)	1009 (299-2268)	857 (277-1839)	0.398°
CD4%	21.34 <u>+</u> 9.87	26.62 <u>+</u> 8.63	0.004** (1.6918-
			8.8726) ^d
CD8%	46.86 (18.42-68.18)	39.62 (20.28-74.31)	0.013*c
CD4/CD8 Ratio	0.43 (0.13-1.41)	0.63 (0.07-1.75)	0.005**c

209 ^canalysed by mann-whitney test

210 danalysed by independent T-test

211 *p<0.05

212

Since there were eight non-typeable samples, we only included 231 samples to identify the 213 risk factors of high-risk HPV infection in women living HIV. Based on Table 3, the characteristics 214 of samples with and without high-risk HPV infection were analyzed. It was found that marital 215 status varied, with divorced participants making up 22.1% of those with HPV and 77.9% of those 216 without. Married participants constituted 20.3% of the HPV-positive group and 79.7% of the HPV-217 negative group, while single participants represented 31.3% of those with HPV and 68.8% without. 218 Education levels also showed differences; those with less than high school education made up 219 19.8% of the HPV-positive group and 80.2% of the HPV-negative group. Regarding contraception 220

It is made available under a CC-BY 4.0 International license .

- use, 25.2% of those using contraception were HPV-positive compared to 74.8% who were
 negative. The number of sexual partners also correlated with HPV status; 27.3% of those with
- 223 more than five partners were HPV-positive.
- 224
- **Table 3.** Characteristics of samples with and without high-risk HPV infection

Variables	HPV (+) (n, %)	HPV (-) (n, %)	p-value	Odd ratio (95%CI)
Marital Status (n=	=231)			
Divorced	17 (22.1%)	60 (77.9%)		-
Married	28 (20.3%)	110 (79.7%)	0.598	
Single	5 (31.3%)	11 (68.8%)		
Education (n=231)			
<high school<="" td=""><td>17 (19.8%)</td><td>69 (80.2%)</td><td>0 50 48</td><td>-</td></high>	17 (19.8%)	69 (80.2%)	0 50 48	-
≥High School	33 (22.8%)	112 (77.2%)	0.394 ^a	
Occupation (n=23	1)			
Unemployed	17 (23.9%)	54 (76.1%)	0 5709	-
Employed	33 (20.6%)	127 (79.4%)	$0.5/2^{a}$	
Alcohol (n=231)				
Yes	1 (100%)	0 (0%)	0 21 ch	4.694 (3.662-
No	49 (21.3%)	181 (78.7%)	0.210°	6.017)
Contraception (n=	=231)			
Yes	28 (25.2%)	83 (74.8%)	0 2048	1.376 (0.839-
No	22 (18.3%)	98 (81.7%)	<u>0.204</u> "	2.258)
Number of Sexual	l Partner (n=231)			
≥5	18 (27.3%)	48 (72.7%)	0 1 0 0 2	1.406 (0.851-
<5	32 (19.4%)	133 (80.6%)	<u>0.189*</u>	2.323)
Sexual debut year	(n=231)			
<21	38 (24.7%)	116 (75.3%)	0 1149	0.632 (0.351-
≥21	12 (15.6%)	65 (84.8%)	0.114^{u}	1.138)
Viral load (n=176)				
Detected	7 (23.3%)	23 (76.7%)	0 (7)	-
Not detected	29 (19.9%)	117 (80.1%)	$0.0/2^{a}$	
HIV Duration (yea	ars) (n=231)			
≥5	21 (13.6%)	133 (86.4%)	0.000**a	0.362 (0.222-
<5	29 (37.7%)	48 (62.3%)		0.591)
ARV Treatment D	uration (Years) (n=23)	1)		
≤1	20 (52.6%)	18 (47.4%)	<u>0.000**</u>	-

It is made available under a CC-BY 4.0 International license .

2-4	11 (25.6%)	32 (74.4%)		
≥5	19 (12.7%)	131 (87.3%)		
Smoking status (n=23	31)			
Yes	8 (26.7%)	22 (73.3%)	0 4002	-
No	42 (20.9%)	159 (79.1%)	0.480"	
HPV infection history	v (n=231)			
Yes	6 (27.3%)	16 (72.7%)	0 50 <i>c</i> h	-
No	44 (21.1%)	165 (78.9%)	0.380°	
Pap smear history (n=	=231)			
Yes	17 (14.2%)	103 (85.8%)	0 00/***	0.477 (0.282-
No	33 (29.7%)	78 (70.3%)	<u>0.004****</u>	0.806)
HPV Vaccine Status	(n=231)			
No	50 (22.1%)	176 (77.9%)	0 500h	
Yes	0 (0%)	5 (100%)	0.388°	
Gravidity (n=231)				
No gravidity	10 (40%)	15 (60%)	<u>0.060</u>	
<u>≤</u> 2	25 (20%)	100 (80%)		
>2	15 (18.5%)	66 (81.5%)		
Hormonal medication	n (n=231)			
Yes	3 (75%)	1 (25%)	0 022*b	3.622 (1.948-
			0.035	6.737)
No	47 (20.7%)	180 (79.3%)		
Abortion (n=231)				
Yes	15 (17.4%)	71 (82.6%)	0 232a	0.723 (0.420-
			0.232	1.244)
No	35 (24.1%)	110 (75.9%)		
History of STDs (n=2	231)			
Yes	6 (28.6%)	15 (71.4%)	0.412 ^b	
No	44 (21%)	166 (79%)		
Menopause (n=231)				
Yes	4 (16%)	21 (84%)	0.468 ^b	
No	46 (22.3%)	160 (77.7%)		

^aanalysed by chi-square test

^banalysed by fisher's exact test

228

From the analysis presented in Table 4, key findings regarding the characteristics of samples with and without high-risk HPV infection were observed. The age of participants did not show a significant difference, with both HPV-positive and HPV-negative groups having a median age of

232 38 years. However, there was a significant difference in CD4 cell counts; participants with HPV

It is made available under a CC-BY 4.0 International license .

had a median CD4 count of 407 cells/uL, while those without HPV had a higher median of 594 cells/uL. This suggested a lower immune status in the HPV-positive group. Additionally, the percentage of CD4 cells was significantly lower in the HPV-positive participants, averaging 21% compared to 27.44% in the HPV-negative group. The CD8 cell counts were similar between the two groups, but the CD4/CD8 ratio was significantly lower in the HPV-positive group, with a median of 0.44 compared to 0.68 in the HPV-negative group, indicating a more pronounced immune system imbalance in those with high-risk HPV infection.

Variables	HPV (+) (mean <u>+</u> SD or median (min-max)	HPV (-) (mean <u>+</u> SD or median (min-max)	p-value (CI95%)
Age (years)	38 (24-48)	38 (24-50)	<u>0.178^c</u>
CD4# (sel/uL)	407 (65-1214)	594 (103-1680)	0.000**c
CD8# (sel/uL)	881 (299-2268)	854 (277-1839)	0.602 ^c
CD4%	21 <u>+</u> 10.53	27.44 <u>+</u> 7.86	<u>0.000**</u> (-9.6311-(-
			3.2436)) ^d
CD8%	45.72 <u>+</u> 12.08	39.16 (20.28-70.13)	0.002**c
CD4/CD8	0.44(0.11, 1.75)	0(0,0,0,0,1,5,4)	0.000**c
Ratio	0.44 (0.11-1.75)	0.68 (0.07-1.54)	<u>0.000**C</u>

240 Table 4. Characteristics of samples with and without high-risk HPV infection

^canalysed by mann-whitney test

²⁴² ^danalysed by independent T-test

243 *p<0.05

- 244 **p<0.01
- 245

246 *HPV genotyping and cytology results*

In the study, Table 5 and Table 6 provided insights into Pap smear and HPV genotyping 247 results. The Pap smear results showed that 37.7% of the samples were normal, while various 248 249 abnormalities were detected: 2.5% had Atypical Squamous Cells of High Grade (ASC-H), 3.8% had Atypical Squamous Cells of Undetermined Significance (ASC-US), 1.7% had High Grade 250 Squamous Intraepithelial Lesion (H-SIL), and 2.9% had Low Grade Squamous Intraepithelial 251 Lesion (L-SIL). The HPV genotyping revealed that HPV 18 was the most prevalent, found in 252 56.2% of the samples with Cytological abnormalities, significantly higher than other types. HPV 253 16, 51, and 52 were also detected but with lower frequencies. The results from these tables 254 underscored the prevalence of high-risk HPV types among women with HIV and their association 255 with various grades of cervical abnormalities. 256

Table 5. Cytological Abnormalities and HPV genotyping

Variables	Frequency (n=239)

It is made available under a CC-BY 4.0 International license .

Cytological abnormalities	26 (10.87%)
Atypical squamous cells high grade (ASC-H)	6 (2.5%)
Atypical squamous cells of undetermined significance	9 (3.8%)
(ASC-US)	
High Grade Squamous Intraepithelial Lesion (H-SIL)	4 (1.7%)
Low Grade Squamous Intraepithelial Lesion (L-SIL)	7 (2.9%)
HPV DNA universal analysis	
Positive	58 (24.3%)
Negative	181 (75.7%)
HPV genotyping (n=58)	
Single genotyping	40 (69%)
Double genotyping	
16, 18	2 (3.4%)
16, 52	1 (1.7%)
18, 45	3 (5.2%)
18, 52	2 (3.4%)
51, 58	1 (1.7%)
56, 58	1 (1.7 %)
Untypeable	8 (13.8%)
HPV genotypes (n=58)	
HPV 16	7 (12.1%)
HPV 18	16 (27.6%)
HPV 31	4 (6.9%)
HPV 33	1 (1.7%)
HPV 45	3 (5.2%)
HPV 51	2 (3.4%)
HPV 52	9 (15.5%)
HPV 56	9 (15.5%)
HPV 58	9 (15.5%)
HPV 35,39,59,66,68	0 (0%)

258

Table 6. Distribution of samples into cytology groups based on HPV genotypes (n=239)

HDV genetyne	With Cytological	Without Cytological	n voluo
III v genotype	abnormalities (n, %)	abnormalities (n, %)	p-value
HPV 16 (+)	3 (42.9%)	4 (57.1%)	
Other than HPV 16	15 (29.4%)	36 (70.6%)	0.000**
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 18 (+)	9 (56.2 %)	7 (43.8%)	0 000**
Other than HPV 18	9 (21.4%)	33 (78.6%)	0.000

It is made available under a CC-BY 4.0 International license .

Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 31 (+)	2 (50.0%)	2 (50.0%)	
Other than HPV 31	16 (29.6%)	38 (70.4%)	0.000**
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 33 (+)	0 (0.0%)	1 (100.0%)	
Other than HPV 33	18 (31.6%)	39 (68.4%)	-
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 45 (+)	1 (33.3%)	2 (66.7%)	
Other than HPV 45	17 (30.9%)	38 (69.1%)	0.000**
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 51 (+)	1 (50.0%)	1 (50.0%)	
Other than HPV 51	17 (30.4%)	39 (69.6%)	0.000**
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 52 (+)	4 (44.4%)	5 (55.6%)	
Other than HPV 52	14 (28.6%)	35 (71.4%)	0.000**
Negative for HPV	8 (4.4%)	173 (95.6%)	
HPV 58 (+)	0 (0.0%)	9 (100.0%)	
Other than HPV 58	18 (36.7%)	31 (63.3%)	-
Negative for HPV	8 (4.4%)	173 (95.6%)	

260

261 Multivariate analysis of cervical cytological abnormalities' risk factors

Table 7 provided a multivariate analysis of the risk factors for cervical cytological 262 abnormalities in women living with HIV. The analysis revealed that HPV 18 was a significant 263 independent risk factor, with an exponent (B) of 9.029 and a p-value of 0.007, indicating a strong 264 association between HPV 18 infection and the presence of cervical abnormalities. Other HPV 265 types such as HPV 16, 31, 45, 51, and 52 were also analyzed, but they did not show significant 266 associations as their p-values were higher, suggesting less impact on the risk of cervical cytological 267 abnormalities. Additionally, a history of Pap smear screening showed a trend towards reducing the 268 risk of cervical abnormalities, although it was not statistically significant with a p-value of 0.083. 269 The analysis underscored the critical role of HPV 18 in contributing to cervical cytological 270 abnormalities among women with HIV and highlighted the potential protective effect of regular 271 Pap smear screenings. 272

273

Table 7. The effects of all the potential risk factors on the risk of cervical cytological abnormalities in women with HIV in this study (n=239)

Covariates	Exponent (B)	P-value	95% CI
HPV DNA	2.800	0.177	0.629 - 12.45
HPV 16	1.99	0.492	0.280 - 14.155
HPV 18	9.029	0.007**	1.835 - 44.425
HPV 31	3.908	0.300	0.298 - 51.317

It is made available under a CC-BY 4.0 International license .

HPV 45	0.617	0.745	0.034 - 11.327
HPV 51	8.295	0.200	0.327 - 210.262
HPV 52	3.277	0.207	0.519 - 20.680
Papsmear history	0.374	0.083	0.123 - 1.138
ARV treatment duration (≤ 1 year)	0.388	0.212	0.088 - 1.718
Contraception history	2.710	0.065	0.940 - 7.809
Occupation (unemployed)	1.845	0.250	0.650 - 5.235
CD4:CD8 ratio	0.378	0.234	0.076 - 1.876

276

277 Multivariate analysis of high-risk HPV infection risk factors

Table 8 presented a multivariate analysis of the risk factors for high-risk HPV infection in 278 women living with HIV. The findings indicated that a history of contraception use was marginally 279 significant as a risk factor, with an exponent (B) of 2.189 and a p-value of 0.053, suggesting a 280 281 potential association with increased risk of HPV infection. The number of sexual partners and the age at sexual debut did not show significant associations with HPV infection, as indicated by their 282 p-values. Notably, a history of Pap smear screening was significantly associated with a reduced 283 risk of high-risk HPV infection, with an exponent (B) of 0.358 and a p-value of 0.013, highlighting 284 the protective effect of regular screening. The duration of ARV treatment and other factors like 285 gravidity, abortion, and hormonal treatment did not show significant associations with HPV risk. 286 This analysis underscored the importance of Pap smear history in reducing the risk of HPV 287 infection among women with HIV. 288

289

Table 8. The effects of all the potential risk factors on the risk of high-risk HPV infection in women with HIV in this study (n=231)

Covariates	Exponent	P-value	95% CI
	(B)		
Contraception history	2.189	0.053	0.989 - 4.845
Number of sexual partner (≥ 5	1.368	0.463	0.592 - 3.161
people)			
Sexual debut year (≥21 years old)	0.573	0.218	0.236 - 1.390
HIV duration (\geq 5 years)	0.542	0.388	0.135 - 2.175
ARV treatment duration (≤ 1	2.504	0.239	0.544 - 11.519
year)			
Pap smear History	0.358	0.013*	0.160 - 0.802
Gravidity (>2 times)	0.481	0.239	0.142 - 1.628
Abortion	0.682	0.360	0.301 - 1.546
Hormonal treatment	8.319	0.106	0.637 - 108.736
Age	1.020	0.522	0.960 - 1.084
CD4:CD8	0.349	0.093	0.103 - 1.190

It is made available under a CC-BY 4.0 International license .

293 Discussion

294 HR-HPV 18 as a risk factor of cervical abnormalities in women living with HIV

Our study found that HR-HPV 18 as the only significant risk factor of cervical cytological 295 abnormalities, potential of cervical cancer. However, a meta-analysis 2021 represents a different 296 297 scenario where HPV 16 was identified as the most prevalent genotype, particularly in the regions of India, Thailand, and China.(9) Another study of meta-analysis about HPV genotypes in Kenya 298 also showed that HPV 16 as the most common infection, with HPV 18 came second. HPV 16 was 299 consistently identified as the most prevalent genotype in women with abnormal cytology and ICC. 300 For instance, in women with abnormal cytology, HPV 16 was found to be present in 26% of cases, 301 and in women with ICC, its prevalence increased to 37%.(10) This indicates a clear escalation in 302 the prevalence of HPV 16 as the severity of cervical disease increases. Following HPV 16, HPV 303 18 is the second most common genotype in ICC cases, with a prevalence of 24%. This discrepancy 304 highlights the geographical and demographic variations in HPV genotype distribution, which is a 305 306 crucial factor in understanding the epidemiology of HPV and its associated risks for cervical cancer. 307

HPV 18, along with HPV 16, belongs to the high-risk category of HPV genotypes that are 308 strongly associated with the development of cervical cancer. These genotypes are known for their 309 ability to integrate into the host cell DNA, disrupting normal cell functions and leading to the 310 progression of precancerous lesions to invasive cancer.(11) The variation in prevalence between 311 our findings and the previous studies could be attributed to differences in study populations. 312 methodologies, or regional public health practices such as the prevalence of vaccination and 313 screening. This underlines the importance of localized data to inform public health strategies 314 315 effectively. For regions where HPV 18 is more prevalent, targeted interventions to address this specific risk factor are crucial.(10) This includes promoting HPV vaccination that covers HPV 18, 316 enhancing screening programs to detect and treat precancerous changes early, and educating the 317 public and healthcare providers about the risks associated with HPV 18. 318

319

320 Pap smear as an effective preventive measure of cervical cancer

The Pap smear is a critical preventive measure for cervical cancer, particularly significant for HIV-seropositive women in developing countries. As a cytological-based test, the Pap smear has been extensively utilized in developed countries for many years, demonstrating substantial success in reducing both the incidence and mortality of cervical cancer.(12)

One of the primary benefits of the Pap smear is its ability to detect precancerous changes in the cervix, known as cervical intraepithelial neoplasia (CIN), at an early stage. Early detection allows for the effective treatment of these changes before they have the chance to progress to cancer. Consequently, this early intervention significantly contributes to the reduction in mortality associated with cervical cancer, as treatments tend to be more effective at earlier stages.(5,13)

Moreover, the Pap smear is a cost-effective procedure. It does not require highly specialized equipment, which makes it a viable option for many healthcare settings, including those with limited resources typical of developing countries. The success of the Pap smear in developed

countries highlights its potential effectiveness when implemented with regular screenings andproper follow-up care.(5)

Despite its benefits, the implementation of the Pap smear in developing countries faces several challenges. These include a lack of proper infrastructure, insufficient qualified personnel, and limited resources, which can impede the utilization and effectiveness of the Pap smear.(5) Nonetheless, it remains a cornerstone of cervical cancer prevention strategies. There is a pressing need to improve its accessibility and integration into healthcare systems, especially for populations at higher risk, such as HIV-seropositive women.

This study is not without limitation. The cross-sectional nature of this research did indeed 341 restrict the ability to establish causal relationships between high-risk HPV infection and cervical 342 cytological abnormalities. The reliance on self-reported data for certain demographic and 343 behavioral factors might also affect the accuracy of the information collected. This study was 344 conducted in specific region in Indonesia, that was bali, which may not account for regional 345 346 variations in HPV prevalence in Indonesia; nonetheless, this study proved that in Bali, a different type of HPV was found to be more prevalent than the usual high-risk HPV found in other areas in 347 the world. 348

349

350 **Conclusions**

Our research found HR-HPV 18 as a significant risk factor for cervical cytological abnormalities and potentially, cervical cancer in women living with HIV, supporting the indicative measure for a routine pap-smear screening in this specified population. Along with the pap smear, vaccination for HR-HPV 18 also becomes urgently important to be readily supplied in Indonesia.

355

356 Competing interests

- No competing interests is declared in the writing of this manuscript.
- 358

359 Authors' contributions

We would like to thank our outstanding team who have helped us in completing this research;
Study committee: TREAT Asia: Annette Sohn, Thida Chanyachukul; Kirby Institute: Kathy
Petoumenos; Molecular Biology Laboratory Udayana University: Ida Bagus Nyoman Putra Dwija;
Pathology Anatomy Faculty of Medicine Udayana University: Nyoman Winarti; Prof Ngoerah
Hospital VCT Clinic: Komang Sutarni, Made Ratni; WM Medika Clinic - Kerti Praja Foundation
Denpasar: Ni Made Vidia Pratiwi, Ni Kadek Ayu Astuti; Social workers accompanying PLWHA
at VCT Prof Ngoerah Denpasar: ketut Rediten, Dedi Junaedi, Afrina Dili Astuti.

367

368 Funding

369 This study is supported by the U.S. National Institutes of Health's National Institute of Allergy

and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and

371 Human Development, the National Cancer Institute, the National Institute of Mental Health, the

372 National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National

It is made available under a CC-BY 4.0 International license .

373 Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and

Kidney Diseases, and the Fogarty International Center, as part of the International Epidemiology

375 Databases to Evaluate AIDS (IeDEA; U01AI069907). The content of this publication is solely the

- responsibility of the authors and does not necessarily represent the official views of any of the
- 377 governments or institutions mentioned above.
- 378
- **References**
- 380
- Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates
 of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021 Feb
 1;9(2):e161–9.
- Jin ZY, Liu X, DIng YY, Zhang ZF, He N. Cancer risk factors among people living with
 HIV/AIDS in China: A systematic review and meta-analysis. Sci Rep. 2017 Dec 1;7(1).
- Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, et al. Cervical cancer
 risk in women living with HIV across four continents: A multicohort study. Int J Cancer.
 2020 Feb 1;146(3):601–9.
- WHO. Tackling NCDs: 'best buys' and other recommended interventions for the prevention
 and control of noncommunicable diseases; updated (2017) appendix 3 of the Global Action
 Plan for prevention and control of noncommunicable diseases 2013–2020. 2017;
- 392 5. Robbers GML, Bennett LR, Spagnoletti BRM, Wilopo SA. Facilitators and barriers for the
 delivery and uptake of cervical cancer screening in Indonesia: a scoping review. Vol. 14,
 Global Health Action. Taylor and Francis Ltd.; 2021.
- Kementeian Keesehatan RI Indonesia. Kementerian Kesehatan RI. Profil Kesehatan
 Indonesia 2016 Kementrian Kesehatan Indonesia [Internet]. 2017.
- 397 7. Ogu CO, Achukwu PU, Nkwo PO. Prevalence and risk factors of Cervical Cytological abnormalities among human immunodeficiency virus sero-positive females on highly active antiretroviral therapy in Enugu, Southeastern, Nigeria. Asian Pacific Journal of Cancer Prevention. 2019;20(10):2987–94.
- 401 8. WHO. WHO guideline for screening and treatment of cervical pre-cancer lesions for402 cervical cancer prevention. 2021.
- Verrier F, Le Coeur S, Delory T. Cervical human papillomavirus infection (Hpv) and high
 oncogenic risk genotypes among women living with hiv in asia: A meta-analysis. Vol. 10,
 Journal of Clinical Medicine. MDPI; 2021.
- Menon S, Wusiman A, Boily MC, Kariisa M, Mabeya H, Luchters S, et al. Epidemiology
 of HPV genotypes among HIV positive women in Kenya: A systematic review and metaanalysis. PLoS One. 2016 Oct 1;11(10).
- 409 11. Freitas BC, Suehiro TT, Consolaro MEL, Silva VRS. HPV infection and cervical
 410 abnormalities in HIV positive women in different regions of Brazil, a middle-income
 411 country. Asian Pacific Journal of Cancer Prevention. 2016;16(18):8085–91.

It is made available under a CC-BY 4.0 International license .

412 12. Mapanga W, Girdler-Brown B, Feresu SA, Chipato T, Singh E. Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer
414 screening: A systematic review. Vol. 7, Systematic Reviews. BioMed Central Ltd.; 2018.

- 415 13. Asangbeh-Kerman SL, Davidović M, Taghavi K, Kachingwe J, Rammipi KM, Muzingwani
- 416 L, et al. Cervical cancer prevention in countries with the highest HIV prevalence: a review
- 417 of policies. BMC Public Health. 2022 Dec 1;22(1).
- 418